<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01482364</url>
  </required_header>
  <id_info>
    <org_study_id>HS-01-2011</org_study_id>
    <nct_id>NCT01482364</nct_id>
  </id_info>
  <brief_title>BEtter Control of Blood Pressure in Hypertensive pAtients Monitored Using the HOTMAN® sYstem</brief_title>
  <acronym>BEAUTY</acronym>
  <official_title>BEtter Control of Blood Pressure in Hypertensive pAtients Monitored Using the BEtter Control of Blood Pressure in Hypertensive pAtients Monitored Using the HOTMAN® sYstem</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hemo Sapiens, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hemo Sapiens, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate that monitoring hemodynamic parameters and then&#xD;
      applying a predefined algorithm of drug selection (i.e. integrated hemodynamic management -&#xD;
      IHM) improves the control of systolic blood pressure (SBP) at ambulatory blood pressure&#xD;
      monitoring (ABPM) in hypertensive patients, as compared to classical drug selection (i.e.&#xD;
      without IHM) during a 6 months intensive treatment program.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Early BP control in hypertensives guarantees the best prevention of cardiovascular events on&#xD;
      the long term (2007 ESH-ESC Guidelines on the Management of Hypertension; VALUE study).&#xD;
      However, in spite of education efforts and antihypertensive drugs, blood pressure control&#xD;
      rates remain low. The most common cause of uncontrolled BP is inadequate pharmacological&#xD;
      treatment, because the selection of antihypertensive agents is often done independently of&#xD;
      the hemodynamic status of the patient (volemia, peripheral resistance, cardiac inotropy,&#xD;
      heart rate).&#xD;
&#xD;
      Several studies confirmed the value of using impedance cardiography (ICG)-derived hemodynamic&#xD;
      data as an adjunct to therapeutic decision-making in the treatment of hypertension.&#xD;
&#xD;
      Working hypothesis: when it is possible to assess the hemodynamic status, and select&#xD;
      accordingly the most appropriate pharmacological class of antihypertensive treatment, BP&#xD;
      reduction occurs to a greater extent and more rapidly.&#xD;
&#xD;
      In the present study an integrated therapeutic approach (IHM-Integrated Hemodynamic&#xD;
      Management)was applied, aiming at detecting permanent vasoconstriction and/or hypervolemia&#xD;
      and/or hyperinotropy through the HOTMAN System, in order to select the most appropriate&#xD;
      antihypertensive drugs.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absolute change in daytime SBP, under ambulatory conditions (ABPM) after a 6 months follow-up.</measure>
    <time_frame>baseline and after 6 months of treatment</time_frame>
    <description>Absolute change in daytime SBP, under ambulatory conditions (ABPM) after 6 months follow-up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The percentage of normalization of SBP (&lt;135 mmHg) at ABPM</measure>
    <time_frame>baseline and after 6 months of treatment</time_frame>
    <description>The percentage of normalization of SBP (&lt;135 mmHg) at ABPM</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The absolute change from baseline in 24h SBP-ABPM, in 24h DBP-ABPM</measure>
    <time_frame>baseline and after 6 months of treatment</time_frame>
    <description>The absolute change from baseline in 24h SBP-ABPM, in 24h DBP-ABPM</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of side effects</measure>
    <time_frame>from baseline to 6 months of treatment</time_frame>
    <description>Rate of side effects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The normalization of hemodynamics (CI, HR and SSVRI), the normalization of PWV and central BP</measure>
    <time_frame>baseline and after 6 months of treatment</time_frame>
    <description>The normalization of hemodynamics (CI, HR and SSVRI), the normalization of PWV and central BP</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">183</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>HOTMAN-driven therapeutic approach arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>&quot;Hotman-driven&quot; therapeutic approach arm(group IHM) will receive treatment according to the results of the HOTMAN® System.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Control arm will receive usual antihypertensive care according to the 2007 ESH Guidelines.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Integrated hemodynamic management (IHM) - HOTMAN System</intervention_name>
    <description>Therapeutic approach according to HOTMAN System measurement(ICG)results .</description>
    <arm_group_label>HOTMAN-driven therapeutic approach arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Non Integrated Hemodynamic Management (Non-IHM) - HOTMAN System</intervention_name>
    <description>Therapeutic approach according to 2007 ESH Guidelines, regardeless HOTMAN results.</description>
    <arm_group_label>Control arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients of either sex presenting with essential hypertension&#xD;
&#xD;
          -  having sustained hypertension both at office BP (SBP&gt;140 mmHg) and at ABPM (SBP&gt;135&#xD;
             mmHg daytime)&#xD;
&#xD;
          -  treated with 2 to 4 antihypertensive drugs&#xD;
&#xD;
          -  aged ≥ 18 and ≤ 75 years&#xD;
&#xD;
          -  after signature of the Informed Consent Form (ICF)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  pregnant or lactating female&#xD;
&#xD;
          -  type 1 diabetes&#xD;
&#xD;
          -  patients with pacemaker (ventricular/dual chamber)&#xD;
&#xD;
          -  Severe aortic insufficiency&#xD;
&#xD;
          -  severe hypertension (SBP ≥ 180 mmHg and/or DBP ≥110 mmHg)&#xD;
&#xD;
          -  resistant hypertension requiring at least 5 antihypertensive drugs&#xD;
&#xD;
          -  secondary hypertension of any aetiology, such as renal disease, pheocromocytoma, or&#xD;
             Cushing's syndrome&#xD;
&#xD;
          -  serious disorders which may limit the ability to evaluate the efficacy or safety of&#xD;
             the protocol, including cerebrovascular, cardiovascular, renal, respiratory, hepatic,&#xD;
             gastrointestinal, endocrine, metabolic (criteria for metabolic syndrome),&#xD;
             haematological, oncological, neurological, or psychiatric diseases&#xD;
&#xD;
          -  history of the following pathologies within the last 6 months:&#xD;
&#xD;
          -  myocardial infarction&#xD;
&#xD;
          -  unstable angina pectoris&#xD;
&#xD;
          -  percutaneous coronary intervention&#xD;
&#xD;
          -  bypass surgery&#xD;
&#xD;
          -  congestive heart failure stage III-IV&#xD;
&#xD;
          -  left branch bundle block&#xD;
&#xD;
          -  atrial fibrillation&#xD;
&#xD;
          -  hypertensive encephalopathy&#xD;
&#xD;
          -  stroke&#xD;
&#xD;
          -  extreme obesity (BMI &gt; 35)&#xD;
&#xD;
          -  previously enrolled subjects&#xD;
&#xD;
          -  alcohol or drug abuse in the past 2 years&#xD;
&#xD;
          -  planned hospitalization during the study period&#xD;
&#xD;
          -  participation in any other clinical study within 30 days prior to screening visit&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephane Laurent</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hopital europeen Georges Pompidou</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tallinn Hypertension Excellence Centre</name>
      <address>
        <city>Tallin</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital européen Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Milano Hypertension Excellence Center</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Oslo, Ullevaal Hospital</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hypertension Unit, Dpt of Hypertension and diabetology, Medical University of Gdansk</name>
      <address>
        <city>Gdansk</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Estonia</country>
    <country>France</country>
    <country>Italy</country>
    <country>Norway</country>
    <country>Poland</country>
  </location_countries>
  <verification_date>November 2011</verification_date>
  <study_first_submitted>November 28, 2011</study_first_submitted>
  <study_first_submitted_qc>November 29, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 30, 2011</study_first_posted>
  <last_update_submitted>March 23, 2015</last_update_submitted>
  <last_update_submitted_qc>March 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HOTMAN System</keyword>
  <keyword>Hemodynamic integrated management</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

